Genetic Modification of Mouse Bone Marrow by Lentiviral Vector-Mediated Delivery of Hypoxanthine-Guanine Phosphoribosyltransferase Short Hairpin RNA Confers Chemoprotection Against 6-Thioguanine Cytotoxicity

Transplantation Proceedings

Volumn 45, Issue 5, 2013, Pages 2040-2044

  Hacke, K ^a   Treger, J A ^a   Bogan, B T ^a   Schiestl, R H ^a   Kasahara, N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; LENTIVIRUS VECTOR; SHORT HAIRPIN RNA; TIOGUANINE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; CELL PROTECTION; CELL VIABILITY ASSAY; DNA MODIFICATION; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO CULTURE; MOUSE; NEUROBLASTOMA CELL LINE; NONHUMAN; PRIORITY JOURNAL; TRANSPLANTATION CONDITIONING; VIRAL GENE THERAPY; ANIMAL; BONE MARROW; ENZYMOLOGY; GENE VECTOR; GENETICS; LENTIVIRINAE; RNA INTERFERENCE; TUMOR CELL LINE;

ANIMALS; BONE MARROW; BONE MARROW TRANSPLANTATION; CELL LINE, TUMOR; GENETIC VECTORS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; LENTIVIRUS; MICE; RNA INTERFERENCE; RNA, SMALL INTERFERING; THIOGUANINE;

EID: 84891480145     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2013.01.020     Document Type: Article

References (25)

1. Copelan, E.A., Hematopoietic stem-cell transplantation. N Engl J Med 354:17 (2006), 1813–1826.
2. de la Morena, M.T., Gatti, R.A., A history of bone marrow transplantation. Hematol Oncol Clin North Am 25:1 (2011), 1–15.
3. Hossle, J.P., Seger, R.A., Steinhoff, D., Gene therapy of hematopoietic stem cells: strategies for improvement. News Physiol Sci 17 (2002), 87–92.
4. Williams, D.A., Hsieh, K., DeSilva, A., et al. Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow. J Exp Med 166:1 (1987), 210–218.
5. Mickisch, G.H., Aksentijevich, I., Schoenlein, P.V., et al. Transplantation of bone marrow cells from transgenic mice expressing the human MDR1 gene results in long-term protection against the myelosuppressive effect of chemotherapy in mice. Blood 79:4 (1992), 1087–1093.
6. Milsom, M.D., Williams, D.A., Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection. DNA Repair (Amst) 6:8 (2007), 1210–1221.
7. Neff, T., Beard, B.C., Kiem, H.P., Survival of the fittest: in vivo selection and stem cell gene therapy. Blood 107:5 (2006), 1751–1760.
8. Zielske, S.P., Reese, J.S., Lingas, K., et al. In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning. J Clin Invest 112:10 (2003), 1561–1570.
9. Larochelle, A., Choi, U., Shou, Y., et al. In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene. J Clin Invest 119:7 (2009), 1952–1963.
10. Trobridge, G., Beard, B.C., Kiem, H.P., Hematopoietic stem cell transduction and amplification in large animal models. Hum Gene Ther 16:12 (2005), 1355–1366.
11. Adair, J.E., Beard, B.C., Trobridge, G.D., et al. Extended survival of glioblastoma patients after chemoprotective HSC gene therapy. Sci Transl Med, 4(133), 2012 133ra57.
12. Schambach, A., Baum, C., Vector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. DNA Repair (Amst) 6:8 (2007), 1187–1196.
13. Hacke, K., Szakmary, A., Cuddihy, A.R., et al. Combined preconditioning and in vivo chemoselection with 6-thioguanine alone achieves highly efficient reconstitution of normal hematopoiesis with HPRT- deficient bone marrow. Exp Hematol 40:1 (2012), 3–13e3.
14. Leung, R.K., Whittaker, P.A., RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther 107:2 (2005), 222–239.
15. Haga, K., Lemp, N.A., Logg, C.R., et al. Permanent, lowered HLA class I expression using lentivirus vectors with shRNA constructs: averting cytotoxicity by alloreactive T lymphocytes. Transplant Proc 38:10 (2006), 3184–3188.
16. Stewart, S.A., Dykxhoorn, D.M., Palliser, D., et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9:4 (2003), 493–501.
17. Grimm, D., Kay, M.A., RNAi and gene therapy: a mutual attraction. Hematology Am Soc Hematol Educ Program, 2007, 473–481.
18. Matrai, J., Chuah, M.K., VandenDriessche, T., Recent advances in lentiviral vector development and applications. Mol Ther 18:3 (2010), 477–490.
19. Sakuma, T., Barry, M.A., Ikeda, Y., Lentiviral vectors: basic to translational. Biochem J 443:3 (2012), 603–618.
20. Dull, T., Zufferey, R., Kelly, M., et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 72:11 (1998), 8463–8471.
21. Porter, C.C., DeGregori, J., Interfering RNA-mediated purine analog resistance for in vitro and in vivo cell selection. Blood 112:12 (2008), 4466–4474.
22. Grimm, D., Streetz, K.L., Jopling, C.L., et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441:7092 (2006), 537–541.
23. An, D.S., Qin, F.X., Auyeung, V.C., et al. Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol Ther 14:4 (2006), 494–504.
24. Boudreau, R.L., Martins, I., Davidson, B.L., Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther 17:1 (2009), 169–175.
25. Boudreau, R.L., Monteys, A.M., Davidson, B.L., Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA 14:9 (2008), 1834–1844.